PubMed Health⌕ Search

PubMed · 12528057

Sleep and epilepsy.

Abstract

Quality sleep is essential for patients with epilepsy, but this aspect of their treatment is frequently overlooked. Sleep disturbance can result in daytime drowsiness, worsening memory, and deteriorating seizure control. In a few patients, recognition and treatment of a coexisting sleep disorder can make the difference between complete seizure control and refractory epilepsy. Sleep has effects on interictal epileptiform discharges, with particular implications for diagnostic studies. Sleep disorders can coexist with epilepsy, leading to errors in diagnosis and worsening of seizures. Some specific syndromes demonstrate unique properties related to sleep. Seizures themselves disrupt sleep, even when occurring during the day, with the potential for persistent drowsiness and, perhaps, further memory dysfunction. Finally, most patients with epilepsy are treated with anticonvulsant drugs, some of which can have adverse (or beneficial) effects on sleep.

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

Carl W Bazil. 2002. Sleep and epilepsy.. https://doi.org/10.1055/s-2002-36651

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

A double-blind placebo-controlled trial of zonisamide (zonegran) in the treatment of essential tremor.

Medical therapy for essential tremor (ET), a common movement disorder, is often inadequate. We performed a double-blind placebo-controlled randomized trial to evaluate the efficacy and tolerability of zonisamide (ZNS), an antiepileptic agent, in treating ET. Twenty patients (mean age, 60 +/- 15 years) with ET were randomized to receive ZNS or placebo. ZNS was initiated at a dosage of 100 mg/day and escalated to 200 mg/day at day 14. Patients were evaluated by accelerometry and the Fahn-Tolosa-Marin (FTM) rating scale at baseline and days 14 and 28, as well as the Clinical Global Impression (CGI-C) scale at day 28. At endpoint, subjects assigned to ZNS were taking a mean dosage of 160 +/- 50 mg/day. There were no significant improvements in the FTM total score or its subsections. Tremor amplitude as assessed by accelerometry significantly improved in the ZNS group compared to the placebo group at endpoint relative to baseline (-0.50 +/- 0.72 vs. 0.30 +/- 0.79 m/s(2); P = 0.03). On the CGI-C, 60% (n = 6) of patients in the ZNS group felt that their tremor was unchanged, while the remaining patients felt that their tremor was "minimally improved." Thirty percent (n = 3) of patients taking ZNS discontinued the study due to side effects (fatigue, headache, paresthesias) while taking 100 mg per day. ZNS did not provide significant improvements in clinical rating scales at study endpoint compared to placebo and was only modestly well tolerated. ZNS was effective in reducing tremor amplitude as measured by accelerometry.

Anticonvulsants↗